Introduction
Corticosteroids are comparable to endogenous glucocorticoids both in structure and function, they bind to the physiological glucocorticoid cytosolic receptor and influence DNA transcription in all parts of the body. Since they were introduced into British medical practice in 1948 for the treatment of rheumatoid arthritis (RA), the potent anti-inflammatory and immunosuppressive properties ofcorticosteroids have led to their use in a variety of rheumatic and other diseases. There is even a current debate as to whether such drugs should be prescribed more widely in RA. Even from the earliest days, it has been recognized that corticosteroid therapy is associated with many undesirable side effects but, since therapy was employed to control severe diseases with high morbidity and mortality, the risk of these complications was considered acceptable. However, today there are often alternatives to steroid therapy and the risk to benefit ratio of this class of drugs requires closer scrutiny before treatment is considered. The prognosis of systemic lupus erythematosus (SLE), for example, has greatly improved in the post-steroid era. However, despite a better prognosis for lupus-related complications, many patients survive only to suffer a high rate of premature cardiovascular complications, prompting us to question whether these events may be a consequence of therapy -in particular, prolonged treatment with oral corticosteroids.
Such a hypothesis deserves further analysis. The demonstration of increased cardiovascular disease due to corticosteroid therapy would have major implications for patients with a variety of other less pernicious diseases sometimes controlled by steroids, such as mild RA. In this article, we discuss the evidence that corticosteroids induce vascular damage and highlight the mechanisms that might underlie this association by linking our current understanding of the actions of glucocorticoids with the pathophysiology of vascular disease.
Evidence for steroid-related damage
The potential problems and benefits of steroid therapy can be assessed by examining its impact on morbidity and survival in chronic steroidresponsive diseases (Table I) .
The outlook for patients with SLE has improved greatly during the last few decades since the introduction of corticosteroids. The survival rate has risen from less than 50% at 4 years in the early 1950s,' to more tha 70% at 10 years by 19802 and has continued to improve. The improved survival has been parallelled by an increased usage of corticosteroids, although earlier [20] [21] [22] [23] An effect of corticosteroids on the heart in RA is also implied by a report ofan increased incidence of electrocardiographic (ECG) abnormalities in patients on low-dose steroids when compared to non-steroid treated controls.24 This group found ST and T wave abnormalities five times more frequent in those controlled on steroids. Peripheral vascular disease was also found to be considerably more common in a corticosteroid-treated group (60%) than a group of controls (20%).25 Necropsy studies of patients with RA have also noted a high incidence of coronary disease.2627
Steroids and non-rheumatic disease
Corticosteroids became widely available in 1955 for use in the treatment of reversible airways obstruction and remain effective in controlling airway inflammation. Robinette and Fraumeni28 examined the 'all cause' mortality over a 29-year period in a cohort of 9,550 war veterans hospitalized with asthma during [1944] [1945] . When compared with a control group hospitalized at the same time with 'acute nasopharyngitis' the relative risk of death from ischaemic heart disease was 1.46 (P<0.001) and from stroke was 1.51 (P<0.05). 99 Fibrinogen production has been shown to increase in response to glucocorticoids both in vitro'00-102 and in vivo. 103, 104 The natural defence to fibrin deposition and clot formation is the fibrinolytic system, initiated by tissue plasminogen activator. Although there are no studies of the overall changes in fibrinolytic activity in response to corticosteroids, cellular production of plasminogen activator by both the mouse macrophage and human neutrophil is blocked by corticosteroids.'05106 Clearly this aspect of glucocorticoid activity may be crucial to intravascular pathology and requires further investigation.
There is further potential for corticosteroids to cause disruption of the thrombosis-fibrinolysis balance by their effects on limiting the availability ofarachidonic acid for prostacyclin synthesis in the vascular wall.107" 08 Glucocorticoids stimulate DNA transcription to produce lipocortin, a protein that inhibits phospholipase A2.' " -i4 This prevents the formation ofproducts ofboth the cyclooxygenase and lipoxygenase systems, including prostaglandins, prostacyclin, leukotrienes and thromboxanes. It would appear that there is a proportionally 
Conclusions
In view of their adverse effects on a number of cardiovascular risk factors, it is surprising that a possible relationship between corticosteroid usage and cardiovascular damage has not been more thoroughly investigated. A considerable body of evidence has been presented that, at the very least, casts suspicion about the effects of the agents currently in widespread use. The lack of attention previously given to this subject probably reflects the fact that therapy is usually given to those of older age who are already prone to the high incidence of age-related atheroma or to younger patients with serious multi-system diseases often involving widespread vasculitis. Under these circumstances a small but genuine effect could be masked. In summary, there is good evidence in the literature to support the contention that regular systemic treatment with corticosteroids is associated with an increase in the incidence of major cardiovascular disease. Several mechanisms may predispose corticosteroid users to an increased risk of atherosclerosis and thrombosis and further research is required to test this hypothesis. As physicians we are obliged to consider the situation and the therapeutic options carefully before starting our patients on long-term steroid therapy.
It is hoped that, in the future, safer and less toxic steroid-sparing agents will be available. In the mean time, although steroids may have a lifesaving role in general diseases, their dosage should be reviewed regularly by prescribers to lessen the subsequent complications of long-term therapy. 
